RetroSense Therapeutics Receives $6,000,000 Series A Funding Round

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=43be5801-b784-4fdc-918a-9fb5b49c9259
Date
1/10/2015
Company Name
RetroSense Therapeutics
Mailing Address
330 East Liberty Street LL Ann Arbor, MI 48104 USA
Company Description
Led by a team of seasoned veterans, RetroSense Therapeutics was founded in 2009 to develop a novel gene therapy approach to vision restoration.
Website
http://www.retro-sense.com
Transaction Type
Venture Equity
Transaction Amount
$6,000,000
Transaction Round
Series A
Proceeds Purposes
The company intends to use the funds to enable completion of preclinical studies needed to support an Investigational New Drug (IND) filing with the U.S. Food and Drug Administration for its lead compound, RST-001 for the treatment of Retinitis Pigmentosa, a cause of vision loss and blindness.
M&A Terms
Venture Investor
Venture Investor
Venture Investor
Venture Investor
Venture Investor